Articles By Estel Grace Masangkay

71. Novartis' Secukinumab Excels In 2 Phase 3 Trials In AS 10/28/2014

    Novartis posted positive results from two Phase 3 trials investigating its drug AIN457 (secukinumab) in ankylosing spondylitis, a debilitating spine disorder.

72. NIH Starts Phase 1 Trial Of NewLink Ebola Vaccine 10/28/2014

    The National Institutes of Health (NIH) announced that it has begun the Phase 1 trial of its second investigational Ebola vaccine VSV-ZEBOV.

73. Arbor's Sotylize For Arrhythmia Approved By The FDA 10/28/2014

    Arbor Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular, pediatric, and hospital markets announced the U.S. Food and Drug Administration (FDA) approval of Sotylize (sotalol hydrochloride) oral solution for the treatment of ventricular arrhythmias. 

74. Research Team Discovers How To Slow Antibiotic Resistance 10/27/2014

    With the help of computer simulations, a research team from the University of Bristol has found how bacteria destroy antibiotics and how the process can be slowed down.

75. FDA Awards Orphan Status To TWi Pharma's Rare Skin Disease Drug 10/27/2014

    TWi Pharmaceuticals reported that its subsidiary TWi Biotechnology has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its drug AC-201 as treatment for rare skin disease epidermolysis bullosa (EB).

76. Sanofi, Regeneron Launch Dupilumab Phase 3 Study In Atopic Dermatitis 10/24/2014

    Sanofi and partner Regeneron Pharmaceuticals announced the launch of the Phase 3 study investigating dupilumab in moderate to severe atopic dermatitis (AD) with the dosing of the first patient.

77. Lilly, Boehringer Ingelheim NDA For Diabetes Combo Accepted By FDA 10/24/2014

    Eli Lilly together with its partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin/metformin fixed-dose combination as treatment for Type 2 diabetes.

78. FDA Approves Genzyme's Label Expansion Of MS Drug Aubagio 10/24/2014

    Sanofi company Genzyme announced the approval of the U.S. Food and Drug Administration (FDA) for the U.S. label of its multiple sclerosis drug Aubagio to include additional safety and efficacy data

79. FDA Panel Backs Novartis' Secukinumab For Psoriasis 10/23/2014

    Novartis announced that it has received the full support of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the U.S. Food and Drug Administration (FDA) for the regulatory approval of its drug secukinumab as treatment for moderate-to-severe plaque psoriasis.

80. Janssen, Pharmacyclics File sNDA For Imbruvica In WM 10/23/2014

    Janssen Research & Development reported that its partner Pharmacyclics has filed a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for Imbruvica as treatment for a rare type of B-cell lymphoma known as Waldenstrom's macroglobulinemia (WM).